Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The role of the synaptic vesicle protein 2A (SV2A) protein, target of the antiepileptic drug levetiracetam, is still mostly unknown. Considering its potential to provide in vivo functional insights into the role of SV2A in epileptic patients, the development of an SV2A positron emission tomography (PET) tracer has been undertaken. Using a 3D pharmacophore model based on close analogues of levetiracetam, we report the rationale design of three heterocyclic non‐acetamide lead compounds, UCB‐A, UCB‐H and UCB‐J, the first single‐digit nanomolar SV2A ligands with suitable properties for development as PET tracers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
SV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-35 · Cited by 43
Self-citation
Cited by
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Self-citationRadiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 337
Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296
“Representative SV2A ligands and corresponding human SV2A pIC50 (11) compared with levetiracetam (LEV) pIC50 (19).”
BackgroundSelf-citationSynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“…tridimensional pharmacophore model of levetiracetam and strict analogs, new compounds were designed with the same specificity and eventually higher affinity for SV2A than the drug itself, including UCB-A, UCB-H and UCB-J; these molecules are suitable for PET radiolabeling (Mercier et al., 2014).”
BackgroundImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“Recently a series of novel PET radiotracers selectively targeting SV2A have been developed (Figure 8) (Mercier et al., 2014; Estrada et al., 2016; Nabulsi et al., 2016; Becker et al., 2017; Li et al., 2019; Cai et al., 2020a), enabling non-invasive observation and quantification of synaptic density…”
BackgroundEvaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85
“As previously demonstrated (10), the in vitro ADME profile showed moderate clearance in rat and human microsomes, a marked ability to permeate CACO-2 cells, and no significant P-glycoprotein– mediated efflux.”
BackgroundSelf-citationSynaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
Self-citationFinnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65
Self-citationMeasuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61
“[(18)F]UCB-H is an original biomarker showing binding specificity for SV2A ([10,11]; Supplementary Data).”
BackgroundSelf-citationLi, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Self-citationRadiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58
Warnier, C., Lemaire, C., Becker, G., Zaragoza, G., Giacomelli, F., Aerts, J., Otabashi, M., Bahri, M. A., Mercier, J., Plenevaux, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00905 · Cited by 58
Self-citationKinetics and 28-day test–retest repeatability and reproducibility of [ 11 C]UCB-J PET brain imaging
Tuncel, H., Boellaard, R., Coomans, E. M., de Vries, E. F., Glaudemans, A. W., Feltes, P. K., García, D. V., Verfaillie, S. C., Wolters, E. E., Sweeney, S. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20964248 · Cited by 45
Angarita, G. A., Worhunsky, P. D., Naganawa, M., Toyonaga, T., Nabulsi, N. B., Li, C. R., Esterlis, I., Skosnik, P. D., Radhakrishnan, R., Pittman, B., et al. (2022) · Addiction Biology · doi:10.1111/adb.13123 · Cited by 38
Thomsen, M. B., Jacobsen, J., Lillethorup, T. P., Schacht, A. C., Simonsen, M., Romero-Ramos, M., Brooks, D. J., & Landau, A. M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20931140 · Cited by 38
“In human studies, K1 values have been reported to be in a more physiological range.11 UCB-J was initially developed alongside two other SV2A ligands, UCB-A and UCB-H.22 PET uptake of [18F]UCB-H has previously been investigated in rats.23 As in the current study, they found high and rapid brain uptake with highest bind…”
BackgroundSynaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31
Self-citationQuantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging
Sadasivam, P., Fang, X. T., Toyonaga, T., Lee, S., Xu, Y., Zheng, M.-Q., Spurrier, J., Huang, Y., Strittmatter, S. M., Carson, R. E., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01567-9 · Cited by 31
“discovery of SV2A ligands with nanomolar IC50 and improved physicochemical properties for brain PET imaging [24].”
BackgroundVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
Interaction of Approved Drugs with Synaptic Vesicle Protein 2A
Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700003 · Cited by 19
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Metadata
- Authors
- Mercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., Kenda, B., Lallemand, B., Michel, P., Montel, F., Moureau, F., Price, N., Quesnel, Y., Sauvage, X., Valade, A., & Provins, L.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2014-01-20
- Volume
- 9
- Issue
- 4
- Pages
- 693-698
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2088762673
- Cited by
- 68
- References
- 5
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.